Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

This study has been terminated.
Dartmouth-Hitchcock Medical Center
Harvard Medical School
Commonwealth Research Center, Massachusetts
Information provided by:
National Institute of Mental Health (NIMH) Identifier:
First received: September 10, 2005
Last updated: February 21, 2006
Last verified: September 2005

This study will examine the physical responses brought on by clozapine and haloperidol in people experiencing their first episode of schizophrenia.

Condition Intervention Phase
Drug: Clozapine
Drug: Haloperidol
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Clozapine or Haloperidol in First Episode Schizophrenia

Resource links provided by NLM:

Further study details as provided by National Institute of Mental Health (NIMH):

Primary Outcome Measures:
  • Clinical Measures: Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Clinical Global Impression, and a neuropsychological battery.

Secondary Outcome Measures:
  • Quality of Life Scale ; safety assessment included complete blood counts, and extrapyramidal symptom scales. Biological measures: plasma and urinary samples of dopamine, norepinephrine and their metabolites and serum prolactin and plasma cortisol.

Estimated Enrollment: 44
Study Start Date: March 1996
Estimated Study Completion Date: July 2003
Detailed Description:

This is a longitudinal double blind, 2- 5 year study of the clinical, neuroendocrine and biochemical response to clozapine (CLOZ) and haloperidol (HAL) in a group of "first episode" schizophrenic (RDC) patients. Within the protocol, we compare the differential effects of the two drugs over the short term (12 weeks) and the long-term (2-5 years); we evaluate the relationship between change in prolactin level and clinical response of the patients; and we search for biochemical predictors and correlates of clinical response. To achieve the study aims, we employ a drug-washout period, a 12-week acute treatment period; and an 88 - 260 week follow-up period.


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • RDC diagnosis of schizophrenia
  • Men and women, without regard to race/ethnicity,
  • Aged 18-45
  • Acutely psychotic with a score of at least 3 on one of the psychotic scale items of the Brief Psychiatric Rating Scale (BPRS) (hallucinations, delusions, conceptual disorganization) and a total BPRS of > 21 (on a 0 - 6 scale);
  • Require treatment with neuroleptic drugs on a clinical basis;
  • The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent;
  • Be within the first episode of a psychotic disorder;
  • Have a history of neuroleptic treatment of < 12 weeks;
  • Likely to remain in the study for 2 years.

Exclusion Criteria:

  • Substance dependence in the last six months
  • History of seizure or blood dyscrasia
  • Major medical illness
  • Pregnancy or Lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00169091

United States, Massachusetts
Commonwealth Research Center
Jamaica Plain, Massachusetts, United States, 02130
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Harvard Medical School
Commonwealth Research Center, Massachusetts
Principal Investigator: Alan I Green, MD Harvard Medical School
  More Information

Publications: Identifier: NCT00169091     History of Changes
Other Study ID Numbers: MH52376
Study First Received: September 10, 2005
Last Updated: February 21, 2006
Health Authority: United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):

Additional relevant MeSH terms:
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Haloperidol decanoate
Anti-Dyskinesia Agents
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
GABA Agents
GABA Antagonists
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents processed this record on March 31, 2015